First Interchangeable Biosimilar to Humira Gets FDA Approval
Ankylosing Spondylitis Arthritis/rheumatic Disorders Colorectal Disorders Crohn Disease Dermatological Disorders Gastroenterology General Musculoskeletal Disorders News Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis

First Interchangeable Biosimilar to Humira Gets FDA Approval

The Food and Drug Administration has approved Cyltezo® (adalimumab-adbm) as the first interchangeable biosimilar to Humira® (adalimumab). Cyltezo, a tumor necrosis factor (TNF) blocker, is indicated to treat adults with rheumatoid arthritis, psoriatic arthritis, ankylosing…